Koronavirüs enfeksiyonları ve yeni düşman: COVID-19

Year 2020, , 118 - 127, 23.04.2020

Öznur Uludag

https://doi.org/10.30569/adiyamansaglik.716011

Cited By: 6

Abstract

Koronavirüsler, şiddetli ani solunum yetmezliği sendromu (SARS), Orta Doğu solunum sendromu (MERS) ve 2019 koronavirüs hastalığı (COVID-19) gibi insanların sağlığı ve yaşamları üzerinde önemli bir etkiye sahip küresel salgınlarla sonuçlanan enfeksiyonlara neden olmuşlardır. Tüm dünya 2019 Aralıktan bu yana COVID-19 enfeksiyonu ile mücadele etmektedir. Enfeksiyon her geçen gün daha çok insanı etkilemekte olup henüz etkin tedavisi bilinmemektedir. SARS ve MERS enfeksiyonlarını anlamak, COVID-19 enfeksiyon mücadele sürecinde bizlere yol gösterecektir. Bu makalede koronavirüslerin genel özellikleri, epidemiyoloji, hastalığın klinik özellikleri ile ilgili mevcut bilgilerin yanı sıra tedavi önerileri özetlenmektedir.

Keywords

Koronavirüs, Şiddetli ani solunum yetmezliği sendromu, Orta Doğu solunum sendromu, Koronavirüs-19

Coronavirus infections and new enemy: COVID-19

Abstract

Coronaviruses, which have a significant impact on people’s health and life, have caused infections that result in global outbreaks such as severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and 2019 coronavirus disease (COVID-19). The whole world has been battling the COVID-19 infection since December 2019. Infection affects more and more people day by day and its effective treatment is not known yet. Understanding SARS and MERS infections will guide us through the COVID-19 infection control process. This article summarizes general features of coronaviruses and the current information on epidemiology, clinical features of the disease, as well as treatment recommendations

Keywords

Coronavirus, Severe acute respiratory syndrome, Middle East respiratory syndrome, Coronavirus-19

References

• 1. Holmes KV. Coronaviruses. In: D. Knipe ea, editor. Fields' Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins. 2001;1187–203.
• 2. Sampathkumar P, Temesgen Z, Smith, TF, Thompson RL. SARS: epidemiology, clinical presentation, management, and infection control measures. Mayo Clin Proc. 2003; 78:882-90.
• 3. Choudhry H, Bakhrebah M, Abdulaal WH, et.al. Middle East respiratory syndrome: pathogenesis and therapeutic developments. Future Virol. 2019; 14:237-46. doi: 10.2217/fvl-2018-0201.
• 4. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/media-resources/press-briefings. Erişim Tarihi: 11.02.2020
• 5. Drexler JF, Corman VM, Drosten C. Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. AntiviralRes.2014;101:45-56. doi:10.1016/j.antiviral.2013.10.013.
• 6. Perlman S., Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nat. Rev. Microbiol. 2009; 7:439–50. doi: 10.1038/nrmicro2147.
• 7. Carlos Franco-Paredes MC, Pablo Kuri-Morales, MC, Carlos Alvarez-Lucas, CD, et.al. Síndrome agudo respiratorio severo: un panorama mundial de la epidemia. Salud pública de méxico. 2003; 45:211-20.
• 8. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289: 2801-09.
• 9. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361:1767-72. doi:10.1016/S0140-6736(03)13412-5.
• 10. Hon KLE, Leung CW, Cheng WTF, et al. Clinical presentations and outcome of severe acute respiratory syndrome in children. Lancet. 2003; 17: 1701-03.
• 11. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361:1319-25.
• 12. Abdel-Moneim AS. Middle East respiratory syndrome coronavirus (MERS-CoV): evidence and speculations. Archives of Virology. 2014; 159: 1575–84.
• 13. Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016; 62:477-83. doi:10.1093/cid/civ951
• 14. Poon LL, Chan KH, Wong OK, et al. Detection of SARS coronavirus in patients with severe acute respiratory syndrome by conventional and real-time quantitative reverse transcription-PCR assays. Clin Chem. 2004; 50:67-72. doi:10.1373/clinchem.2003.023663.
• 15. Wit E, Doremalen N, Falzarano D, Munster JV. SARS and MERS: recent insights into emerging coronaviruses. Nature Reviews Microbiology. 2016; 14:523–34.
• 16. Jin M, Tong Q. Rhabdomyolysis as Potential Late Complication Associated with COVID-19. Emerg Infect Dis. 2020; 20:26. doi: 10.3201/eid2607.200445.
• 17. Wan S, Xiang Y, Fang W, et al. Clinical Features and Treatment of COVID-19 Patients in Northeast Chongqing. Journal of Medical Virology. 2020 doi: 10.1002/jmv.25783.
• 18. Mao L, Wang M, Chen S,et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. doi.org/10.1101/2020.02.22.20026500.
• 19. Zhou F, Yu X, Tong X, Zhang R. Clinical features and outcomes of 197 adult discharged patients with COIVD-19 in Yichang, Hubei. doi.org/10.1101/2020.03.26.20041426.
• 20. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms. ACS Chem. Neurosci. 2020. doi.org/10.1021/acschemneuro.0c00122.
• 21. Braun E, Sauter D. Furin‐mediated protein processing in infectious diseases and cancer. Clin Transl Immunology. 2019; 8(8): e1073. doi: 10.1002/cti2.1073.
• 22. https://www.nnchaber.com/sigara-icenlerde-coronanin-etkisi. Erişim Tarihi:31.03.2020.
• 23. Chinese Center for Disease Control and Prevention. Guidelines for Epidemiological Investigation of COVID-19 [EB/OL]. (in Chinese) (2020-03-09)12020-03-15]. http: //www.chinacdc.cn/jkzt/crb/zl/szkb_ 11803/jszl_ 11815/202003/120200309 214241.html.
• 24. www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.
• 25. Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism. School of Life Science and Food Engineering, Yibin University, China. 2020. Erişim: https://chemrxiv.org/articles/COVID19_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin/11938173.
• 26. https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf. Erişim Tarihi:14.04.2020.
• 27. Biot C, Daher W, Chavain N, et al. Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities. J. Med. Chem. 2006; 49:2845-49.
• 28. Chen X. Hydroxychloroquine and chloroquine. Clin Infect Dis. 2020; 26. pii: ciaa338. doi: 10.1093/cid/ciaa338.